CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- 4 Grant or award Director acquired 775 shares (grant or award)
- 4 Grant or award Director acquired 775 shares (grant or award)
- 4 Gift Chief Executive Officer gave 41,311 shares (gift)
- 4 Planned sale CMO & EVP Dev & Med Affairs sold 9,766 shares at an average $293.36 ($2,864,985)
- 4 Planned sale Director sold 7,440 shares at $299.00 ($2,224,560)
- 4 Exercise or conversion Director acquired 2,750 shares (option exercise)
- 4 Grant or award EVP, CLO and Secretary acquired 757 shares (grant or award)
- 4 Planned sale CSO & EVP, Head of Research sold 2,755 shares at an average $242.94 ($669,304)
- 4 Open-market sale EVP, Chief Commercial Officer sold 471 shares at an average $243.78 ($114,820)
- 4 Planned sale CMO & EVP Dev & Med Affairs sold 2,557 shares at an average $242.92 ($621,150)
- 4 Open-market sale EVP, Chief Financial Officer sold 1,264 shares at an average $243.78 ($308,141)
- 4 Open-market sale Chief Executive Officer sold 3,877 shares at an average $243.79 ($945,165)
- 4 Open-market sale Chief Executive Officer sold 2,900 shares at an average $241.69 ($700,894)
- 4 Open-market sale EVP, Chief Financial Officer sold 796 shares at an average $241.70 ($192,390)
- 4 Open-market sale EVP, Chief Commercial Officer sold 513 shares at an average $241.68 ($123,983)
- 4 Open-market sale CMO & EVP Dev & Med Affairs sold 935 shares at an average $241.69 ($225,977)
- 4 Open-market sale CSO & EVP, Head of Research sold 496 shares at an average $241.69 ($119,878)
- 4 Open-market sale Chief Executive Officer sold 1,213 shares at an average $255.17 ($309,527)
- 4 Open-market sale EVP, Chief Financial Officer sold 967 shares at an average $255.17 ($246,750)
- 4 Planned sale CSO & EVP, Head of Research sold 2,103 shares at an average $252.71 ($531,448)
Page 5 of 47 · 936 filings